))
Validation of L-type calcium channel blocker amlodipine as a novel ADHD treatment through cross-species analysis, drug-target Mendelian randomization, and clinical evidence from medical records
Manage episode 486835593 series 3452336
Content provided by Marina Ostankovitch and Springer Nature. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Marina Ostankovitch and Springer Nature or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Attention deficit hyperactivity disorder, or ADHD, is a common condition that, for a lot of people, is difficult to treat. The drugs that exist have a number of adverse side effects, and about 25 percent of patients don’t respond to existing drugs. And so a team of researchers in Iceland, led by Karl Karlsson, professor of biomolecular engineering at Reykjavik University, undertook a number of different steps to narrow in on and then test what the team has determined to be a novel treatment for ADHD, using an existing drug, amlodipine.
Read the full study here: https://www.nature.com/articles/s41386-025-02062-x
Hosted on Acast. See acast.com/privacy for more information.
60 episodes
Share
